According to the main indicatorsof Healthy China Construction, the market scale of health care in big health industry in China will exceed 8trillion yuan in 2020. The industry will enter the golden decade in thefuture. In this circumstance, Rupert HoogewerfResearch Institute, provides high-quality ranking list and research, jointlyreleased the "2020 Big Health White Paper of Yingkang Life &RupertHoogewerf Research Institute" together with Yingkang Life.
In the past 70 years, the healthlevel of Chinese residents has been continuously improved, and the average lifespan has increased from 35 to 77 years old. With its main health indicators aresuperior to the average level of middle and high-income countries. Which solvedthe problem of medical treatment for one sixth of the world's population withrelatively small investment. Medical and health undertakings in China haveembarked on a road with Chinesecharacteristics.
Under the background that "Healthy China" has become anational strategy, "investing inhealth" can promote the transformation of "demographic dividend"into "health dividend" and inject new vitality into economicdevelopment. The rapid growth of China's health industry is due to the hugepopulation base and the increasingly severe aging problem, and also thecontinuous guidance and strong support of national policies.
Bighealth industry is a collective concept, if expanded from the field ofindustrial chain, which including medical device manufacturing, medicalservices and bio-safety.
· Since the 21st century,with the rapid increase of medical demand brought by the improvement of livingstandards and the aging population, as well as a series of national policies toencourage the innovation and import substitution of domestic medical devices,the whole domestic medical device manufacturing industry has stepped into astage of rapid growth. The sales scale of China's medical device market hasincreased from 120 billion yuan in 2010 to 3, 08 billion yuan in 2015. Themedical device market maintains a 20% growth rate from 2015 to 2020.
·Comparedwith the international market, China's medical device market has a huge growthspace. The scale of medical device market in developed countries has beenequivalent to that of drug market in the same period, while the market ofmedical device in China is only 1 / 5 of that in the same period, and therewill be broad space for growth in the future.
数据来源，国家统计局Source: National Bureauof statistics·As a high-performancemedical device, tumor radiotherapy equipment has always attracted greatattention. In a broad sense, there are more than 10 kinds of tumor radiotherapyequipment. Gamma knife treatment because of its good cost performance willstill be the main equipment of radiotherapy in China on the current situationand for a long time in the future.
·Gamma knife treatmentis a rare large-scale medical equipment in China, with its technology in thetop level worldwide
伽玛刀是国内少有的大型医疗设备技术处于世界领先的领域。
·There is a big gap inthe penetration of radiotherapy equipment in China compared with developedcountries such as Europe, America and Japan. According to the statistical dataof the World Health Organization, by the end of 2013, China had only 1.1radioactive treatment equipment per million people, far lower than the percapita level of developed countries.
·With the rapid growth of China'seconomy, the contradiction between the overall shortage of medical services(hospitals, professional rehabilitation institutions,recuperating services, etc.) and the continuous growth of demand hasbecome increasingly prominent in the social background of the risingurbanization rate, the aging population, and the implement of the two childpolicy, the surge of medical expenditure willingness and the upgrade ofconsumption. At the same time, since the new medical reform in 2009, the scale of medical service market hasgrown steadily, and social medical service has ushered in unprecedenteddevelopment opportunities.
·Thenumber of non-public hospitals exceeds that of public hospitals, reaching 14500. But itis still facing the problem of with large number but of low quality, it is at adisadvantage in terms of number of beds and the number of diagnosis andtreatment.
非公医院数量超公立医院，达到14,500家，但仍是“多而不强”，在床位数、诊疗量等方面均处于劣势。
数据来源：国家卫健委
Datasource: National Health Commission· Among all kinds ofspecialized hospitals, the top three types of average revenue is Tumo hospital,Chest hospital and Children's hospital.
各类专科医院中平均营收入排名前三的专科类型是：肿瘤医院、胸科医院、儿童医院。
· With a variety ofsocial capitals actively develop medical treatment industry, and the momentumof non-public hospital collectivization is strong. From the perspective of thetypes of social capital participants in non-public hospitals, the mostrepresentatives in China are the four major non-public medical groups includingCR Medical, CITIC Medical&Health,PKU Heal Thcare and Fosun Pharma.
· At present, we have a quite numberof non-public hospitals in China, and the next step we are facing now is how tochange the situation from quantitative changes to qualitative changes.
目前，我国非公医院数量已发展到了一定的规模，下一步面临的将是如何从量变到质变。
Bio-Safety
生物安全
· In the 21st century, biotechnologyis developing rapidly worldwide, and the scale of related industries isexpanding continuously, which plays an important role in solving the crisis offood, population, resources, energy, environment and so on. It is inparticular, the rise and development of genetic engineering technology, hasmade the impact of modern biotechnology on human being more and more obvious,and the industries related to biotechnology have gradually become one of thepillar industries of the domestic economy in the 21st century. Biosafetyemerges with the birth of genetic engineering, science and technology is alwaysa double-edged sword, while benefiting human beings, its potential negativeeffects are also exposed. Therefore, biosafetyhas become a hot issue in the whole society.
·In2018, the scale of biological industry reached nearly 5 trillion yuan. The main businessincome and profit of enterprises above designated size in pharmaceuticalindustry increased by 13.34% and 10.82% respectively over the same period oflast year. Among them, the above indicators of "manufacturing of geneticallyengineered drugs and vaccines" and "manufacturing of medicalequipment and devices" reached 34.4% and 24.1% respectively.
·Therise of domestic demand is closely related to the vigorous development ofChina's biomedical field. The consumption of scientificresearch and clinical biological samples, as well as drugs, vaccines and bloodis increasing day by day, and the safety of its storage and use has alsoattracted more and more attention.
From 2011 to 2018, the compoundannual growth rate of cryogenic storage market of domestic biomedical was4.44%, with a higher increase than that of the global market.
